NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland. Show more

Location: Neuhofstrasse 21, Baar, 6340, Switzerland | Website: https://www.novocure.com | Industry: Medical Devices | Sector: Healthcare


Market Cap

1.993B

52 Wk Range

$14.17 - $34.13

Previous Close

$17.88

Open

$17.90

Volume

1,315,434

Day Range

$17.68 - $18.30

Enterprise Value

1.752B

Cash

929.1M

Avg Qtr Burn

-7.615M

Insider Ownership

9.84%

Institutional Own.

87.40%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Optune Lua Details
Non-small cell lung carcinoma

Approved

Update

Phase 3

Data readout

Phase 3

Update

Phase 3

Update

Phase 3

Update

Phase 3

Update

Phase 2

Data readout